Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HLA-A2-WT1/anti-CD3 T-cell engaging bispecific antibody RO7283420

A T-cell receptor (TCR)-like T-cell engaging bispecific antibody (T-BsAb) targeting both the RMFPNAPYL nonapeptide (RMF peptide), which is derived from the intracellular Wilms tumor 1 (WT1; WT-1) and presented on human leukocyte antigen A2 (HLA-A2), and the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-HLA-A2-WT1/anti-CD3 T-cell engaging bispecific antibody RO7283420 simultaneously binds to both CD3 on cytotoxic T lymphocytes (CTLs) and the HLA-A2 WT1 complex found on WT1-expressing tumor cells. This activates and redirects CTLs to WT1-expressing tumor cells, which results in the CTL-mediated cell death of WT1-expressing tumor cells. WT1, an intracellular oncoprotein and transcription factor, is overexpressed in a variety of tumor cell types.
Synonym:HLA-A2-WT1 x CD3 RG6007
HLA-A2-WT1xCD3 T-cell engaging bispecific antibody RO7283420
RMF-peptide-MHC-specific T-cell bispecific antibody RG6007
Code name:RG 6007
RG-06007
RG6007
RO 7283420
RO-7283420
RO7283420
Search NCI's Drug Dictionary